预防性使用头孢吡肟对肝硬化失代偿期上消化道出血患者院内感染的影响

张莹; 邵琼; 熊丽

doi:10.3969/j.issn.1671-038X.2017.05.12

预防性使用头孢吡肟对肝硬化失代偿期上消化道出血患者院内感染的影响

- 1. 鄂州市中心医院重症医学科, 湖北鄂州 436000;
- 2. 鄂州市中心医院药学部, 湖北鄂州 436000;
- 3. 鄂州市中心医院检验科, 湖北鄂州 436000

详细信息

作者简介:
张莹,女,本科,研究方向:重症临床

通讯作者: 熊丽,E-mail:13995809128@163.com

中图分类号: R575.2

收稿日期: 2016-11-25

Effect of prophylactic use of Cefepime on nosocomial infection in cirrhosis patients with upper digestive tract hemorrhage

- 1. Department of Critical Medicine, Ezhou Central Hospital, Hubei 436000, China;
- 2. Department of Pharmacy, Ezhou Central Hospital, Hubei 436000, China;
- 3. Department of Laboratory, Ezhou Central Hospital, Hubei 436000, China

More Information

Corresponding author: XIONG Li, E-mail: 13995809128@163.com

Received Date: 25 November 2016

摘要

摘要: [目的]观察预防性使用头孢吡肟对肝硬化失代偿期上消化道出血患者院内感染的预防作用，以及相关的临床意义。[方法]2014年7月~2016年7月我院收治的肝硬化失代偿期上消化道出血患者88例，使用信封法将88例患者随机分为对照组和观察组，每组44例。对照组给予基础治疗对症治疗，观察组在对照基础上预防性使用头孢吡肟1 g溶于100 ml 0.9%氯化钠注射液中，静滴，1次/d，连续用药7 d。比较2组院内感染、再出血、死亡发生率，以及凝血酶原时间和住院天数的差异。[结果]2组患者院内感染主要以腹腔感染为主，其次为呼吸道和胃肠道感染，观察组的院内感染发生率为27.3%（12/44），显著低于对照组的52.3%（23/44）（P<0.05）。观察组再出血发生率为22.7%（10/44），显著低于对照组的40.9%（18/44）（P<0.05）。观察组死亡率为18.2%（8/44），显著低于对照组的38.6%（17/44）（P<0.05）。观察组血酶原时间为（16.14±1.37） s，显著低于对照组的（17.32±1.52） s （P<0.05）。观察组的住院时间为（15.61±2.72） d，显著短于对照组的（21.82±4.16） d （P<0.05）。2组之间感染的病原菌种类差异无统计学意义（P>0.05）。[结论]预防性使用头孢吡肟可以显著减低肝硬化失代偿期上消化道出血患者院内感染的发生率，降低患者的再出血发生率和死亡率。
- 头孢吡肟 /
- 肝硬化失代偿期 /
- 上消化道出血 /
- 院内感染
Abstract: [Objective] To detect the effect of prophylactic use of Cefepime on nosocomial infection in cirrhosis patients with upper digestive tract hemorrhage.[Methods] 88 cirrhosis patients with upper digestive tract hemorrhage were enrolled in this study and randomly divided into control group and observation group, with each group of 44 cases.The control group was given basic treatment, and the observation group was given Chloride(1 g, 1 times/d, continuous 7 d) on the basis of control group.The difference of hospital infection, rebleeding, mortality, prothrombin time, and length of hospital stay was compared between the two groups.[Results] The two groups of patients with nosocomial infection were mainly abdominal infection, followed by respiratory and gastrointestinal infections.The incidence rate of nosocomial infection in observation group was 27.3%(12/44), which was significantly lower than that of 52.3%(23/44) in control group(P<0.05).The incidence rate of re bleeding in observation group was 22.7%(10/44), which was significantly lower than that of 40.9%(18/44) in control group(P<0.05).The mortality rate of the observation group was 18.2%(8/44), which was significantly lower than that of 38.6%(17/44) in control group(P<0.05).The prothrombin time in observation group was 16.14 ±1 37 s, which was significantly lower than that of 17.32 ±1 52 s in control group(P<0.05).The length of hospital stay in observation group was 15.61 ±2.72 d, which was significantly shorter than that of 21.82 ± 4.16 d in control group(P<0.05).There was no significant difference of pathogenic bacteria between the two groups(P>0.05).[Conclusion] Prophylactic use of Cefepime significantly reduced the incidence of nosocomial infection in cirrhosis patients with upper digestive tract bleeding, which also reduced the incidence of recurrent hemorrhage and mortality.
- Cefepime /
- cirrhosis patients /
- upper digestive tract bleeding /
- nosocomial infection

HTML全文

参考文献(12)

[1]	Poordad F F.Presentation and complications associated with cirrhosis of the liver[J].Curr Med Res Opin, 2015, 31:925-937.
[2]	陈英杰.肝硬化患者上消化道出血与细菌感染的相关性研究[J].慢性病学杂志, 2016, 17(1):77-78.
[3]	Garcia-Tsao G.Current Management of the Complications of Cirrhosis and Portal Hypertension:Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis[J].Dig Dis, 2016, 34:382-386.
[4]	李孝楼, 陈明胜, 甘巧蓉, 等.肝硬化上消化道出血预防性抗感染治疗失败的影响因素[J].临床肝胆病杂志, 2016, 32(2):288-291.
[5]	中华医学会消化病学分会, 中华医学会肝病学分会, 中华医学会内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治共识[J].中华肝脏病杂志, 2008, 16(8):564-570.
[6]	中华人民共和国卫生部.医院感染诊断标准(试行)[J].中华医学杂志, 2001, 81(5):314-326.
[7]	董红筠, 高斌, 王敬, 等.乙型肝炎肝硬化合并上消化道出血患者医院感染的相关因素分析[J].中华医院感染学杂志, 2014, 24(8):1955-1957.
[8]	Poca M, Alvarado-Tapias E, Concepcion M, et al.Predictive model of mortality in patients with spontaneous bacterial peritonitis[J].Aliment Pharmacol Ther, 2016, 44:629-637.
[9]	Pleguezuelo M, Benitez JM, Jurado J, et al.Diagnosis and management of bacterial infections in decompensated cirrhosis[J].World J Hepatol, 2013, 27, 5:16-25.
[10]	Jindal A, Kumar M, Bhadoria AS, et al.A randomized open label study of ‘imipenem vs.cefepime’ in spontaneous bacterial peritonitis[J].Liver Int, 2016, 36:677-687.
[11]	Fernandez J, Tandon P, Mensa J, et al.Antibiotic prophylaxis in cirrhosis:Good and bad[J].Hepatology, 2016, 63:2019-2131.
[12]	赵新英, 王雨存, 潘素荣, 等.消化内科医院感染病原菌分析与预防[J].中华医院感染学杂志, 2016, 26(10):2290-2292.